Literature DB >> 29040714

NICE issues positive recommendation for XELJANZ®▼(tofacitinib citrate) as a new treatment option for adults with severe rheumatoid arthritis.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29040714     DOI： 10.1093/rheumatology/kex407

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN： 1462-0324            Impact factor:   7.580


× No keyword cloud information.
  2 in total

1.  Targeting Upstream Kinases of STAT3 in Human Medulloblastoma Cells.

Authors:  Jia Wei; Ling Ma; Chenglong Li; Christopher R Pierson; Jonathan L Finlay; Jiayuh Lin
Journal:  Curr Cancer Drug Targets       Date:  2019       Impact factor: 3.428

Review 2.  JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders.

Authors:  William Vainchenker; Emilie Leroy; Laure Gilles; Caroline Marty; Isabelle Plo; Stefan N Constantinescu
Journal:  F1000Res       Date:  2018-01-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.